source
- CellCentric secures $220 million Series D to advance oral multiple myeloma drug inobrodibCellCentric, a biotech focused on multiple myeloma, announced a $220 million Series D financing led by Venrock. The capital will fund ongoing Phase 2 trials and a planned Phase 3 study of its oral…
- Bayer agrees to acquire ophthalmology biotech Perfuse Therapeutics for $300 million upfrontBayer announced it will purchase Perfuse Therapeutics, a company focused on eye-disease treatments, for an upfront payment of $300 million. The acquisition includes Perfuse's mid-stage program that…